Author Index: S

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
IMPROVING CERVICAL CANCER PRIMARY SCREENING AND DIAGNOSTIC FOLLOW-UP IN AUSTRIA – A DECISION-ANALYTIC BENEFIT-HARM ANALYSIS

HEALTH-ECONOMIC EVALUATION OF HPV-BASED CERVICAL CANCER PRIMARY SCREENING COMPARED TO CYTOLOGY OR P16/KI-67 DUAL-STAINING – A DECISION-ANALYSIS FOR THE AUSTRIAN HEALTH CARE CONTEXT

LONG-TERM EFFECTIVENESS AND COST EFFECTIVENESS OF DIFFERENT ANTIVIRAL TREATMENTS FOR CHRONIC GENOTYPE-1 HCV INFECTION IN GERMANY INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR

DIRECT ANTIVIRAL DRUGS FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 OR 4 IN FRANCE - COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR BY FIBROSIS SUBGROUP

THE BENEFIT-HARM BALANCE OF PROSTATE CANCER SCREENING IN MEN WITH AVERAGE AND ELEVATED FAMILIAL RISK – PREDICTIONS OF THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL

BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE

AN OVERVIEW OF DIFFERENT MAPPING TECHNIQUES TO DERIVE HEALTH STATE UTILITY VALUES IN MULTIPLE MYELOMA FOR DECISION-ANALYTIC MODELING

COSTS OF FIRST-LINE TREATMENT FOR ELDERLY MULTIPLE MYELOMA PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM

META-ANALYSIS AND INDIRECT TREATMENT COMPARISON OF SAFETY PROFILES OF BORTEZOMIB- AND THALIDOMIDE-BASED REGIMENS FOR THE FIRST LINE TREATMENT OF ELDERLY TRANSPLANT-INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

TREATMENT STRATEGIES FOR MULTIPLE MYELOMA IN ELDERLY PATIENTS: A NETWORK META-ANALYSIS

SMDM CORE COURSE: INTRODUCTION TO MEDICAL DECISION ANALYSIS (DECISION-ANALYTIC MODELING)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z